DOCSLIB.ORG

Study of Genetic and Epigenetic Alterations in Urine Samples As Diagnostic Markers for Prostate Cancer

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Study of Genetic and Epigenetic Alterations in Urine Samples As Diagnostic Markers for Prostate Cancer ANTICANCER RESEARCH 33: 191-198 (2013) Study of Genetic and Epigenetic Alterations in Urine Samples as Diagnostic Markers for Prostate Cancer EFTHYMIOS DIMITRIADIS1, THEODOROS KALOGEROPOULOS2, STAMATIA VELAETI1, SOTIRIOS SOTIRIOU4, EVANGELOS VASSILIOU5, LOUKAS FASOULIS2, VASILIOS KLAPSAS2, MICHALIS SYNESIOU2, AIKATERINI APOSTOLAKI3, THEONI TRANGAS4 and NIKOLAOS PANDIS1 1Department of Genetics 2Urology and 3Pathology, St. Savvas Anticancer Hospital, Athens, Greece; 4Department of Biological Applications and Technologies, University of Ioannina, Ioannina, Greece; 5Department of Financial and Management Engineering, School of Business, University of Aegean, Chios, Greece Abstract. Background: Early diagnosis of prostate cancer and Prostate cancer is one of the most frequently diagnosed types identification of new prognostic factors remain main issues in of non-skin cancer and a leading cause of cancer-related prostate cancer research. In this study, we sought to test a deaths for men worldwide (1). Diagnosis and management panel of cancer-specific markers in urine samples as an aid for are complicated by the lack of cancer-specific markers to early cancer diagnosis. Materials and Methods: Sedimented assist for diagnosis during the early stages of the disease, and urine samples of 66 candidates for needle biopsy were tested. to predict and monitor response to therapy. Real time-polymerase chain reaction (RT-PCR) was applied to The use of prostate-specific antigen (PSA) as a screening detect the expression of transmembrane protease serine-2 and and monitoring marker for prostate cancer is widespread (2). Ets-related gene fusion (TMPRSS2–ERG), Ets-related gene Although PSA monitoring has led to higher prostate cancer (ERG), prostate cancer antigen-3 (PCA3), and serine peptidase detection rates, it has also substantial drawbacks. PSA is inhibitor kazal type-1 (SPINK1) transcripts. For testing of the specific for tissues of prostatic origin but is not cancer-specific. methylation status of Glutahione S-tranferase P (GSTP1) and Serum PSA levels are often elevated in benign prostatic Ras association domain family member-1(RASSF1A) promoter hyperplasia and prostatitis. Thus, the PSA testing is associated region, methylation-specific PCR (MSP-PCR) was applied. with a significant false-positive rate, with a high proportion Results: Among the tested parameters, the presence of (>50%) of the resulting biopsies proving negative for cancer. TMPRSS2–ERG (OR=9.044, 95% CI=2.207-37.066, Furthermore, studies have also indicated that low levels of PSA p=0.002), as well as a positive test result for PCA3 do not preclude prostate cancer, and that 15% of men with PSA (OR=7.549, 95% CI=1,858-30,672, p=0.005) were associated 0-4 mg/ml developed prostate cancer (3). Moreover large with the subsequent diagnosis of prostate cancer. A randomized trials assigned modest effects upon mortality rates multivariable logistic regression including all the significantly of PSA screening during the first decade of follow-up (4, 5). associated variables [prostate-specific antigen (PSA), digital Thus the need for non-invasive methods that can accurately rectal examination (DRE), TMPRSS2-ERG and PCA3], yielded assist in the early detection of prostate cancer, still exists. To a model with area under the receiver-operating characteristic address this issue, additional markers have been investigated curve (AUC) =0.894 (95% CI=0.772-1.00). Conclusion: A including genetic and epigenetic alterations. Among those the multiplexed quantitative PCR analysis on sedimented urine, in most promising are: Genes that are specifically overexpressed conjunction with the results of serum PSA levels and DRE, has in prostate cancer cells, such as prostate cancer antigen-3 the potential to accurately foresee subsequent needle biopsy (PCA3), alpha methyl-CoA racemase (AMACR), serine outcomes. On the basis of the above, algorithms may be peptidase inhibitor kazal type1 (SPINK1) (6-8); prostate designed to guide decisions for needle biopsy. cancer-specific gene alterations, mainly the fusion genes involving transmembrane protease serine-2 (TMPRSS2) and E-twenty six (ETS) family members (9); and prostate cancer- specific methylation alterations of gene promoter regions Correspondence to: Efthymios Dimitriadis, Department of Genetics, Glutahione S-tranferase P (GSTP1), Ras association domain St. Savvas Anticancer Hospital, Alexandras Ave 171, 11522, Athens, Greece. E-mail: [email protected] family member 1(RASSF1A) (10, 11). Taking advantage of the fact that prostate cells can be Key Words: Prostatic neoplasms, carcinoma, gene expression, detected in blood and urine, prostate cancer-specific markers diagnostic markers, urine. can be tested through a urine or blood diagnostic test (12). 0250-7005/2013 $2.00+.40 191 ANTICANCER RESEARCH 33: 191-198 (2013) The goal of the present study was to assess the diagnostic Table I. Sequence of primers, probes and annealing temperatures (TM). efficacy of a number of markers associated with malignant transformation when used individually or combined, in order Primer, probe Sequence TM to achieve a pre-biopsy prediction of prostate cancer and TMRSS2–ERGa2F cgc ggc agg aag cct ta 60˚C contribute to early diagnosis in a non-invasive manner. TMRSS2–ERGa2R tcc gta ggc aca ctc aaa caa c TMRSS2–ERG probe cag ttg tga gtg agg acc Materials and Methods PSA Fw gtc tgc ggc ggt gtt ctg 60˚C PSA Rw tgc cga ccc agc aag atc PSA probe cac agc tgc cca ctg cat cag ga Urine collection and DNA and RNA isolation. This study was PSA_SGfw gca tca gga aca aaa gcg tga 60˚C approved by the St. Savvas Anticancer Hospital Scientific PSA_SGRw cct gag gaa tcg att ctt cag Committee and informed consent was obtained from all participants. PCA3_SGFw cat ggt ggg aag gac ctg atg ata c 60˚C Urine samples were collected from 66 men who were admitted for PCA3_SGRw gat gtg tgg cct cag atg gta aag tc transrectal ultrasound (TRUS)-guided prostate biopsy at the SPINK1_SGFw caa aaa tct ggg cct tgc tga gaa c 60˚C Department of Urology in St. Savvas Anticancer Hospital on the SPINK1_SGRw agg cct cgc ggt gac ctg at basis of PSA level and/or abnormal DRE. At least 30 ml of urine ERG5-6_SGFw cgc aga gtt atc gtg cca gca gat 60˚C sample were collected from each patient immediately following a ERG5-6_SGRw cca tat tct ttc acc gcc cac tcc DRE. All patients included in this study were referred for prostate RASSFIA_methF gtg tta acg cgt tgc gta tc 56˚C biopsy for the first time. RASSFIA_methR aac ccc gcg aac taa aaa cga Urine was voided into sterile collection cups containing 5 ml of RASSFIA_unmethF ttt ggt tgg agt gtg tta atg tg 0.5 M EDTA. A minimum of 30 ml of the collected urine was RASSFIA_unmethR caa acc cca caa act aaa aac aa centrifuged at 5000 ×g for 20 min at 4˚C and the resulting cell pellet GSTP1_methF ttc ggg gtg tag cgg tcg t 56˚C was processed for DNA and RNA extraction. GSTP1_methR gcc cca ata cta aat cac gac g GSTP1_unmethF gat gtt tgg ggt gta gtg gtt gtt Total RNA and DNA was isolated using an RNA, DNA GSTP1_unmethR cca ccc caa tac taa atc aca aca extraction kit (NucleoSpin RNAXS, NucleoSpin RNA/DNA buffer set; Macherey-Nagel, Duren, Germany), according to the TMPRSS2: Transmembrane protease serine-2; ERG: Ets-related gene; manufacturer’s instructions. PSA: prostate-specific antigen; PCA3: prostate cancer antigen 3, SPINK1: serine peptidase inhibitor kazal type1; RASSF1A: Ras Quantitative reverse transcription-polymerase chain reaction association domain family member 1; GSTP: Glutahione S-tranferase (qRT-PCR). Quantitative RT-PCR was used to assess the P; SG: Syber Green. expression of four biomarkers [transmembrane protease serine2 and Ets related gene fusion (TMPRSS2–ERG), Ets related gene (ERG), PCA3, SPINK1] and the PSA transcript as control for prostate-derived cells. Total RNA (8 μl) was reverse-transcribed in 20 μl reactions using the SuperScript III First-strand Synthesis PCR conditions, as previously described (13, 14) (Table I). PCR Super Mix (Invitrogen, Carlsbad, California, USA) and random products were electrophoresed on 2.5% agarose gels and visualised hexamers as primers. with ethidium bromide staining. The cDNA was subjected to TaqMan PCR amplification for both the TMPRSS2–ERG fusion gene and PSA transcripts using primers Statistical analysis. Pre-biopsy clinical parameters were compared and PCR conditions, as described in Table I. between men diagnosed with prostate cancer vs. men without All PCR amplifications were performed in 20 μl reaction prostate cancer using Mann-Whitney tests for continuous variables mixture, containing 1× Platinum Quantitative PCR Super Mix and Fisher’s exact tests for categorical variables. Exact univariate (Invitrogen), 5 pmol of each primer and 5 pmol of TaqMan probes. logistic regression was used to examine the association between Syber Green qRT-PCR was applied for PCA3, ERG, SPINK1 and PSA levels, DRE outcome, PCA3 expression levels and PSA control expression using primers and PCR conditions described TMPRSS2–ERG fusion with the presence or absence of prostate in Table I. cancer upon prostate needle biopsy (PNB). All PCR amplifications were performed in 20μl reactions, The performance of each biomarker as a screening test was containing 1× Platinum Syber Green Quantitative PCR Super mix evaluated, and sensitivity, specificity, and the area under the (Invitrogen), and 5 pmol of each primer. receiver-operating characteristic curve (AUC), with 95% confidence The qPCR results for all the genes were calculated using intervals (CI), were calculated (15). A multivariable logistic RelQuant software (Roche Molecular Biochemicals, Mannheim, regression model predicting the diagnosis of prostate cancer on Germany) and are expressed as the ratio of the target gene/PSA biopsy was then developed using backward selection. The initial ×1000. The results were considered valid only if the PSA Ct was model contained PSA, DRE, PCA3 and TMPRSS2–ERG fusion as <35 cycles. potential predictor variables.
Load more

Recommended publications
  • Downloaded Uniformly Processed RNA-Seq Datasets from 3,764,506 High-Throughput Sequencing Samples from Skymap in Raw Count Format19
    Preprints (www.preprints.org) | NOT PEER-REVIEWED | Posted: 28 April 2020 doi:10.20944/preprints202003.0360.v2 TMPRSS2 transcriptional inhibition as a therapeutic strategy for COVID-19 Xinchen Wang, Ph.D.1*, Ryan S. Dhindsa, Ph.D.1,2, Gundula Povysil, M.D., Ph.D.1, Anthony Zoghbi, M.D.1,3,4, Joshua E. Motelow, M.D., Ph.D.1,5, Joseph A. Hostyk, B.Sc.1, Nicholas Nickols, M.D. Ph.D.6,7, Matthew Rettig, M.D.8,9, David B. Goldstein, Ph.D.1,2* 1Institute for Genomic Medicine, Columbia University Irving Medical Center, New York, 2Department of Genetics & Development, Columbia University Irving Medical Center, New York, 3Department of Psychiatry, Columbia University Irving Medical Center, New York 4New York State Psychiatric Institute, New York 5Division of Pediatric Critical Care, Department of Pediatrics, New York-Presbyterian Morgan Stanley Children’s Hospital, Columbia University Irving Medical Center, New York 6Department of Radiation Oncology, University of California, Los Angeles, Los Angeles 7Department of Radiation Oncology, Veteran Affairs Greater Los Angeles Healthcare System, Los Angeles, California 8Division of Hematology and Oncology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles 9Division of Hematology and Oncology, VA Greater Los Angeles Healthcare System, Los Angeles, Los Angeles, California *To whom correspondence should be addressed: [email protected] (X.W.), [email protected] (D.B.G.) Abstract There is an urgent need to identify effective therapies for COVID-19. The SARS-CoV-2 host factor protease TMPRSS2 is required for viral entry and thus an attractive target for therapeutic intervention.
    [Show full text]
  • CREB3L2-Pparg Fusion Mutation Identifies a Thyroid Signaling Pathway Regulated by Intramembrane Proteolysis
    Research Article CREB3L2-PPARg Fusion Mutation Identifies a Thyroid Signaling Pathway Regulated by Intramembrane Proteolysis Weng-Onn Lui,3 Lingchun Zeng,1 Victoria Rehrmann,1 Seema Deshpande,5 Maria Tretiakova,1 Edwin L. Kaplan,2 Ingo Leibiger,3 Barbara Leibiger,3 Ulla Enberg,3 Anders Ho¨o¨g,4 Catharina Larsson,3 and Todd G. Kroll1 Departments of 1Pathology and 2Surgery, University of Chicago Medical Center, Chicago, Illinois; Departments of 3Molecular Medicine and Surgery and 4Oncology-Pathology, Karolinska Institute, Karolinska University Hospital, Stockholm, Sweden; and 5Department of Pathology, Emory University School of Medicine, Atlanta, Georgia Abstract cancer in patients; and (c) the implementation of effective molecular-targeted chemotherapies that have relatively few side The discovery of gene fusion mutations, particularly in effects. The discovery of fusion mutations is therefore important, leukemia, has consistently identified new cancer pathways particularly in carcinoma, the most common cancer group in and led to molecular diagnostic assays and molecular-targeted which few gene fusions have been identified (1). The recent chemotherapies for cancer patients. Here, we report our discoveries of ERG (2) and ALK (3) gene fusions in prostate and discovery of a novel CREB3L2-PPARg fusion mutation in lung carcinoma, respectively, increase the prospect that new thyroid carcinoma with t(3;7)(p25;q34), showing that a family diagnostic and therapeutic strategies based on gene fusions will of somatic PPARg fusion mutations exist in thyroid cancer. The be applicable to common epithelial cancers. CREB3L2-PPARg fusion encodes a CREB3L2-PPAR; fusion Families of gene fusions tend to characterize specific cancer protein that is composed of the transactivation domain of types.
    [Show full text]
  • The Rationale for Angiotensin Receptor Neprilysin Inhibitors in a Multi-Targeted Therapeutic Approach to COVID-19
    International Journal of Molecular Sciences Review The Rationale for Angiotensin Receptor Neprilysin Inhibitors in a Multi-Targeted Therapeutic Approach to COVID-19 Alessandro Bellis 1 , Ciro Mauro 1, Emanuele Barbato 2, Bruno Trimarco 2 and Carmine Morisco 2,* 1 Unità Operativa Complessa Cardiologia con UTIC ed Emodinamica-Dipartimento Emergenza Accettazione, Azienda Ospedaliera “Antonio Cardarelli”, 80131 Napoli, Italy; [email protected] (A.B.); [email protected] (C.M.) 2 Dipartimento di Scienze Biomediche Avanzate, Università FEDERICO II, 80131 Napoli, Italy; [email protected] (E.B.); [email protected] (B.T.) * Correspondence: [email protected]; Tel.: +39-081-746-2253; Fax: +39-081-746-2256 Received: 12 October 2020; Accepted: 11 November 2020; Published: 15 November 2020 Abstract: The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) disease (COVID-19) determines the angiotensin converting enzyme 2 (ACE2) down-regulation and related decrease in angiotensin II degradation. Both these events trigger “cytokine storm” leading to acute lung and cardiovascular injury. A selective therapy for COVID-19 has not yet been identified. Clinical trials with remdesivir gave discordant results. Thus, healthcare systems have focused on “multi-targeted” therapeutic strategies aiming at relieving systemic inflammation and thrombotic complications. No randomized clinical trial has demonstrated the efficacy of renin angiotensin system antagonists in reducing inflammation related to COVID-19. Dexamethasone and tocilizumab showed encouraging data, but their use needs to be further validated. The still-controversial efficacy of these treatments highlighted the importance of organ injury prevention in COVID-19. Neprilysin (NEP) might be an interesting target for this purpose. NEP expression is increased by cytokines on lung fibroblasts surface.
    [Show full text]
  • Markers for Detection of Prostate Cancer
    Cancers 2010, 2, 1125-1154; doi:10.3390/cancers2021125 OPEN ACCESS cancers ISSN 2072-6694 www.mdpi.com/journal/cancers Review Markers for Detection of Prostate Cancer Raymond A. Clarke 1, Horst J. Schirra 2, James W. Catto 3, Martin F. Lavin 4,5 and Robert A. Gardiner 5,* 1 Prostate Cancer Institute, Cancer Care Centre, St George Hospital Clinical School of Medicine, University of New South Wales, Kogarah, NSW 2217, Australia; E-Mail: [email protected] 2 School of Chemistry and Molecular Biosciences, University of Queensland, Brisbane QLD, 4072, Australia; E-Mail: [email protected] 3 Academic Urology Unit and Institute for Cancer Studies, University of Sheffield, Royal Hallamshire Hospital, Sheffield S10 2JF, UK; E-Mail: [email protected] 4 Queensland Institute of Medical Research, Radiation Biology and Oncology, Brisbane, QLD 4029, Australia; E-Mail: [email protected] 5 University of Queensland Centre for Clinical Research, Brisbane, Australia * Author to whom correspondence should be addressed; E-Mail: [email protected]. Received: 22 March 2010; in revised form: 2 June 2010 / Accepted: 3 June 2010 / Published: 4 June 2010 Abstract: Early detection of prostate cancer is problematic, not just because of uncertainly whether a diagnosis will benefit an individual patient, but also as a result of the imprecise and invasive nature of establishing a diagnosis by biopsy. Despite its low sensitivity and specificity for identifying patients harbouring prostate cancer, serum prostate specific antigen (PSA) has become established as the most reliable and widely-used diagnostic marker for this condition. In its wake, many other markers have been described and evaluated.
    [Show full text]
  • Transcription of Nrdp1 by the Androgen Receptor Is Regulated by Nuclear filamin a in Prostate Cancer
    R M Savoy et al. Nrdp1 is an AR target regulated 22:3 369–386 Research by FLNA Transcription of Nrdp1 by the androgen receptor is regulated by nuclear filamin A in prostate cancer Rosalinda M Savoy1,2, Liqun Chen2, Salma Siddiqui1, Frank U Melgoza1, Blythe Durbin- Johnson3, Christiana Drake4, Maitreyee K Jathal1,2, Swagata Bose1,2, Thomas M Steele1, Benjamin A Mooso1, Leandro S D’Abronzo1,2, William H Fry5, Kermit L Carraway III5, Maria Mudryj1,6 and Paramita M Ghosh1,2,5 1VA Northern California Health Care System, Mather, California, USA 2Department of Urology, School of Medicine, University of California Davis, 4860 Y Street, Suite 3500, Correspondence Sacramento, California 95817, USA should be addressed 3Division of Biostatistics, Department of Public Health Sciences, University of California Davis, Davis, California, USA to P M Ghosh 4Department of Statistics, University of California Davis, Davis, California, USA Email 5Department of Biochemistry and Molecular Medicine, University of California Davis, Sacramento, California, USA paramita.ghosh@ucdmc. 6Department of Medical Microbiology and Immunology, University of California Davis, Davis, California, USA ucdavis.edu Abstract Prostate cancer (PCa) progression is regulated by the androgen receptor (AR); however, Key Words patients undergoing androgen-deprivation therapy (ADT) for disseminated PCa eventually " castration-resistant prostate develop castration-resistant PCa (CRPC). Results of previous studies indicated that AR,a cancer transcription factor, occupies distinct genomic loci in CRPC compared with hormone-naı¨ve " AR/androgen receptor " Endocrine-Related Cancer PCa; however, the cause of this distinction was unknown. The E3 ubiquitin ligase Nrdp1 is a FLRF/RNF41/Nrdp1 model AR target modulated by androgens in hormone-naı¨ve PCa but not in CRPC.
    [Show full text]
  • S01-01 Therapeutic Targeting of TMPRSS2 and ACE2 As a Potential Strategy to Combat COVID-19. Qu Deng1, Reyaz Ur Rasool1, Ramakrishnan Natesan1, Irfan A
    S01-01 Therapeutic targeting of TMPRSS2 and ACE2 as a potential strategy to combat COVID-19. Qu Deng1, Reyaz Ur Rasool1, Ramakrishnan Natesan1, Irfan A. Asangani2. 1Department of Cancer Biology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, 2Department of Cancer Biology, Abramson Family Cancer Research Institute, Epigenetics Institute, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA. The novel SARS-CoV-2 infection responsible for the COVID-19 pandemic is expected to have an adverse effect on the progression of multiple cancers, including prostate cancer, due to the ensuing cytokine storm associated oncogenic signaling. A better understanding of the host cell factors and their regulators will help identify potential therapies to block SARS-CoV-2 infection at an early stage and thereby prevent cancer progression. Host cell infection by SARS-CoV-2 requires the binding of the viral spike S protein to ACE2 receptor and priming by the serine protease TMPRSS2—encoded by a well-known androgen response gene and highly expressed in patients diagnosed with prostate cancer. Epidemiologic data showing increased severity and mortality of SARS-CoV-2 disease in men suggest a possible role for androgen in the transcriptional activation of ACE2 and TMPRSS2 in the lungs and other primary infection sites. Here, by performing in vivo castration in mice, RT-PCR, immunoblotting, Co-IP, and pseudovirus infection assays in multiple cell lines, we present evidence for the transcriptional regulation of TMPRSS2 and ACE2 by androgen, their endogenous interaction, as well as a novel combination of drugs in blocking viral infection. In adult male mice, castration led to a significant loss in the expression of ACE2 and TMPRSS2 at the transcript and protein levels in the lung, heart, and small intestine.
    [Show full text]
  • Molecular Pathways: Targeting ETS Gene Fusions in Cancer
    Published OnlineFirst June 23, 2014; DOI: 10.1158/1078-0432.CCR-13-0275 Clinical Cancer Molecular Pathways Research Molecular Pathways: Targeting ETS Gene Fusions in Cancer Felix Y. Feng1,2,3, J. Chad Brenner2,3,4,5, Maha Hussain3,6,7, and Arul M. Chinnaiyan2,3,4,7,8 Abstract Rearrangements, or gene fusions, involving the ETS family of transcription factors are common driving events in both prostate cancer and Ewing sarcoma. These rearrangements result in pathogenic expression of the ETS genes and trigger activation of transcriptional programs enriched for invasion and other oncogenic features. Although ETS gene fusions represent intriguing therapeutic targets, transcription factors, such as those comprising the ETS family, have been notoriously difficult to target. Recently, preclinical studies have demonstrated an association between ETS gene fusions and components of the DNA damage response pathway, such as PARP1, the catalytic subunit of DNA protein kinase (DNAPK), and histone deactylase 1 (HDAC1), and have suggested that ETS fusions may confer sensitivity to inhibitors of these DNA repair proteins. In this review, we discuss the role of ETS fusions in cancer, the preclinical rationale for targeting ETS fusions with inhibitors of PARP1, DNAPK, and HDAC1, as well as ongoing clinical trials targeting ETS gene fusions. Clin Cancer Res; 20(17); 4442–8. Ó2014 AACR. Background tion domain (from the EWS gene) to the ETS fusion and ETS transcription factors are aberrantly expressed in (ii) replacement of the N-terminus of the ETS protein by several cancers, including prostate cancer (1), the Ewing an RNA-binding domain from the EWS protein that sarcoma family of tumors (2), melanoma (3), secretory enhances posttranscriptional splicing of ETS target genes breast carcinoma (4), acute lymphoblastic leukemia (5), (10; Fig.
    [Show full text]
  • Promising Targets and Tools for COVID-19 Prophylaxis and Treatment ACE-2, TMPRSS2 Ve Ötesi; COVİD-19 Profilaksisi Ve Tedavisi Için Umut Vaat Eden Hedefler Ve Araçlar
    Review DOI: 10.14235/bas.galenos.2020.4756 Bezmialem Science 2020;8(Supplement 3):79-83 ACE-2, TMPRSS2 and Beyond; Promising Targets and Tools for COVID-19 Prophylaxis and Treatment ACE-2, TMPRSS2 ve Ötesi; COVİD-19 Profilaksisi ve Tedavisi için Umut Vaat Eden Hedefler ve Araçlar Akçahan GEPDİREMEN1, Meltem KUMAŞ2 1Bezmialem Vakıf University Medical Faculty, Department of Medical Pharmacology, İstanbul, Turkey 2Dokuz Eylül University Faculty of Veterinary Medicine, Department of Histology and Embryology, İzmir, Turkey ABSTRACT ÖZ Several repurposing drugs and ongoing vaccine researches to Başka endikasyonlar için ruhsatlandırılmış birçok ilaç ve aşı combat Coronavirus Disease-19 (COVID-19) are testing clinically, araştırmaları, Koronavirüs Hastalığı-19 (COVİD-19) ile savaşta tüm worldwide. COVID-19 caused by severe acute respiratory failure dünyada klinik olarak denenmektedir. COVİD-19’a yol açan ağır syndrome-CoV-2, uses angiotensin-converting enzyme 2 (ACE- akut solunum yolu yetersizliği sendromu, transmembranal proteaz 2) as a functional receptor for entry into the cells, followed by its serin 2 (TMPRSS2) tarafından hazırlandıktan sonra, hücrelere giriş için fonksiyonel reseptör olarak anjiyotensin dönüştürücü enzim 2’yi priming by transmembrane protease serine 2 (TMPRSS2). Most of (ACE-2) kullanır. En fazla ACE-2 eksprese edilen hücreler; alveoler the ACE-2 expressing cells are alveolar type II pneumocytes. Viral tip 2 pnömositlerdir. Gelecekteki tedavilerin potansiyel hedefleri, S-glycoprotein, TMPRSS2 and ACE-2 inhibition, as extracellular
    [Show full text]
  • Overview of Research on Fusion Genes in Prostate Cancer
    2011 Review Article Overview of research on fusion genes in prostate cancer Chunjiao Song1,2, Huan Chen3 1Medical Research Center, Shaoxing People’s Hospital, Shaoxing University School of Medicine, Shaoxing 312000, China; 2Shaoxing Hospital, Zhejiang University School of Medicine, Shaoxing 312000, China; 3Key Laboratory of Microorganism Technology and Bioinformatics Research of Zhejiang Province, Zhejiang Institute of Microbiology, Hangzhou 310000, China Contributions: (I) Conception and design: C Song; (II) Administrative support: Shaoxing Municipal Health and Family Planning Science and Technology Innovation Project (2017CX004) and Shaoxing Public Welfare Applied Research Project (2018C30058); (III) Provision of study materials or patients: None; (IV) Collection and assembly of data: C Song; (V) Data analysis and interpretation: H Chen; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors. Correspondence to: Chunjiao Song. No. 568 Zhongxing Bei Road, Shaoxing 312000, China. Email: [email protected]. Abstract: Fusion genes are known to drive and promote carcinogenesis and cancer progression. In recent years, the rapid development of biotechnologies has led to the discovery of a large number of fusion genes in prostate cancer specimens. To further investigate them, we summarized the fusion genes. We searched related articles in PubMed, CNKI (Chinese National Knowledge Infrastructure) and other databases, and the data of 92 literatures were summarized after preliminary screening. In this review, we summarized approximated 400 fusion genes since the first specific fusion TMPRSS2-ERG was discovered in prostate cancer in 2005. Some of these are prostate cancer specific, some are high-frequency in the prostate cancer of a certain ethnic group. This is a summary of scientific research in related fields and suggests that some fusion genes may become biomarkers or the targets for individualized therapies.
    [Show full text]
  • Integrin-Linked Kinase As a Target for ERG-Mediated Invasive Properties in Prostate Cancer Models
    Carcinogenesis vol.33 no.12 pp.2558–2567, 2012 doi:10.1093/carcin/bgs285 Advance Access publication October 2, 2012 Integrin-linked kinase as a target for ERG-mediated invasive properties in prostate cancer models Daiana D.Becker-Santos1,2,†, Yubin Guo3,†, TMPRSS2, and coding regions of E twenty-six (ETS) transcription fac- Mazyar Ghaffari3,4, Elaine D.Vickers3, Melanie Lehman3, tors (1) predict disease subtypes in which androgens could promote aber- Manuel Altamirano-Dimas3, Arusha Oloumi1, rant expression of these potential oncogenes (1–3). Fusions of TMPRSS2 Junya Furukawa3, Manju Sharma3, Yuzhuo Wang1,3,5, with ERG are the most common, presenting in approximately half of PCas Shoukat Dedhar1,2,3,6 and Michael E.Cox3,4,5,* (4–6). TMPRSS2 and ERG fusions can occur via reciprocal translocation or interstitial rearrangement, leading to aberrant androgen receptor (AR)- 1Department of Integrative Oncology, British Columbia Cancer Research Centre, mediated expression of full-length or N-truncated ERG protein isoforms. Vancouver, British Columbia, Canada V5Z 1L3, 2Genetics Graduate Program, Prior to identification of TMPRSS2-ERG translocations, ERG was rec- University of British Columbia, Vancouver, Canada V6T 1Z2, 3The Vancouver ognized to be frequently expressed in PCa and to predict decreased dis- Prostate Centre, Vancouver Coastal Health Research Institute, Vancouver, ease-free survival (7). Although the prognostic value of TMPRSS2-ERG 4 British Columbia, Canada V6H 3Z6, Experimental Medicine Program, Faculty rearrangements in subsequent epidemiologic studies have been mixed, of Medicine V5Z 1M9, 5Department of Urologic Sciences V5Z 1M9 and6 amplification of these translocations or linkage with loss of phosphatase Downloaded from Department of Biochemistry and Molecular Biology, University of British Columbia, Vancouver, British Columbia, Canada V6T 1Z3 and tensin homolog (PTEN) predicts poorer prognosis (8–15).
    [Show full text]
  • TMPRSS2-ERG Gene Fusion Is Rare Compared to PTEN Deletions in Stage T1a Prostate Cancer Kurt W
    Revised Manuscript MC-16-0090R2 TMPRSS2-ERG gene fusion is rare compared to PTEN deletions in stage T1a prostate cancer Kurt W. Fisher 1, Shaobo Zhang 1, Mingsheng Wang 1, Rodolfo Montironi 2, Lisha Wang 3, Lee Ann Baldrige 1, Jonas Y. Wang 1, Gregory T. MacLennan4, Sean R. Williamson 5,6,7 , Antonio Lopez-Beltran 8, Liang Cheng 1,2 From the Department of Pathology 1 and Urology 2, Indiana University School of Medicine, Indianapolis, IN; Institute of Pathological Anatomy and Histopathology 2, Polytechnic University of the Marche Region (Ancona), United Hospitals, Ancona, Italy; 3Michigan Center for Translational Pathology 3, University of Michigan, Ann Arbor, MI, USA; Departments of Pathology and Laboratory Medicine 4, Case Western Reserve University, Cleveland, OH, USA; Department of Pathology and Laboratory Medicine 5 and Josephine Ford Cancer Institute 6 , Henry Ford Health System, Detroit, MI, USA; 3Department of Pathology 7, Wayne State University School of Medicine, Detroit, MI, USA; 8Department of Pathology and Surgery, Faculty of Medicine, Cordoba University, Spain and Champalimaud Clinical Center, Lisbon, Portugal. Running Head: Molecular Alterations in T1a Prostate Cancer Keywords: Prostate, Transition zone, insignificant cancer, PTEN loss, TMPRSS2-ERG rearrangement; Fluorescence in situ hybridization; T1a Total number of text pages, 18; Number of tables, 2; Number of figures, 2. Address correspondence and reprint requests to Liang Cheng, M.D., Department of Pathology and Laboratory Medicine,Author Indiana University Manuscript School of Medicine, 350 West 11 th Street, IUHPL Room 4010, Indianapolis, IN 46202, USA. Telephone: 317-491-6442; Fax: 317-491- 6419; E-mail: [email protected] Abstract T1a prostate cancers (cancer found incidentally in transurethral resection, <5% of the tissue) are indolent tumors of the transition zone.
    [Show full text]
  • Androgen Receptor As a Regulator of ZEB2 Expression and Its Implications in Epithelial-To-Mesenchymal Transition in Prostate Cancer
    S Jacob et al. AR as a regulator of ZEB2 21:3 473–486 Research expression in PCa Androgen receptor as a regulator of ZEB2 expression and its implications in epithelial-to-mesenchymal transition in prostate cancer Sheeba Jacob, S Nayak, Gwendolyn Fernandes1, R S Barai2, S Menon3, U K Chaudhari, S D Kholkute and Geetanjali Sachdeva Primate Biology Laboratory, National Institute for Research in Reproductive Health (NIRRH), Correspondence Indian Council of Medical Research, JM Street, Parel, Mumbai 400012, India should be addressed 1GS Medical College and KEM Hospital, Parel, Mumbai 400012, India to G Sachdeva 2The Centre for Medical Bioinformatics, NIRRH, Parel, Mumbai 400012, India Email 3Department of Pathology, Tata Memorial Hospital, Mumbai 400012, India [email protected] Abstract Zinc finger E-box-binding protein 2 (ZEB2) is known to help mediate the epithelial- Key Words to-mesenchymal transition, and thereby it facilitates cancer metastasis. This study was " androgen receptor initiated to explore whether ZEB2 expression differs in prostate cancer (PCa, nZ7) and " EMT benign prostatic hyperplasia (BPH, nZ7) tissues. In PCa tissues, the levels of both " ZEB2 immunoreactive ZEB2 and androgen receptor (AR) were found to be significantly higher " prostate cancer (P!0.05) when compared with BPH tissues. Co-regulation of AR and ZEB2 prompted us to Endocrine-Related Cancer investigate the role of androgenic stimuli in ZEB2 expression. ZEB2 expression was found to be significantly (P!0.05) upregulated after androgen stimulation and downregulated following AR silencing in LNCaP cells, an androgen-dependent PCa cell line. This finding suggested AR as a positive regulator of ZEB2 expression in androgen-dependent cells.
    [Show full text]